重视抗HBV在肝癌治疗中的作用

Anti-HBV playing an important role in therapy of hepatocellular carcinoma

乙型肝炎病毒感染是我国肝癌发生最主要的危险因素,其复制水平也影响着肝癌患者术后并发症的发生。大量的研究已经证实HBV-DNA复制也可以导致肝癌术后复发率的增高,因此,一些临床研究致力于抗HBV治疗能否有效预防肝癌的术后复发。目前大多数的研究表明,抗HBV治疗可以降低肝癌术后复发率,而部分研究结果则认为不能降低肿瘤的复发率,但是可以延长病人的生存时间。对于HBV相关性肝癌,抗HBV治疗无论是在肝癌围手术期的处理还是在预防肝癌术后复发方面,在肝癌治疗的整个过程中均扮演了重要的角色。因此,在肝癌的临床治疗中,必须重视抗HBV的治疗。

Hepatitis B virus infection( HBV) is the major risk factor for hepatocarcinogenesis in China,and the HBV-DNA level also influences the postoperative complications ratio. A lot of research has confirmed that HBV-DNA replication could lead to the tumor recurrence after liver resection. Some clinical research aimed to find whether anti-HBV therapy can prevent the relapse of hepatocellular carcinoma( HCC). At present,majority study confirm that anti-HBV therapy can reduce tumor recurrence ratio of HCC,but some researches find it is useless for the relapse preventing, however,it can prolong the patients survival period. Above all,as for HBV related HCC,anti-HBV therapy plays an important role in the whole HCC therapy process including perioperative treatment and HCC relapse prevention. So,we must pay attention to anti-HBV therapy in HCC treatment.